Drugs in CancerDP
Compound (code or generic name) Class Target(s) Mechanism of action Highest Phase
Erlotinib Kinase inhibitor EGFR EGFR Inhibitor Launched-2004
Lapatinib Kinase inhibitor EGFR, HER2 EGFR and HER2 Inhibitor Launched-2007
PHA-665752 Kinase inhibitor c-MET c-MET Inhibitor Preclinical
PF-2341066 Kinase inhibitor c-MET, ALK c-MET and ALK Inhibitor Launched-2011
TAE684 Kinase inhibitor ALK ALK Inhibitor Preclinical
Vandetanib Kinase inhibitor Abl, EGFR, Flt3, C-KIT, RET, VEGFR-1, KDR, FLT4 Multi-kinase inhibitor Launched-2011
Nilotinib Kinase inhibitor Abl/Bcr-Abl Abl Inhibitor Launched-2007
AZD0530 Kinase inhibitor Src, Abl/Bcr-Abl, EGFR Src and Abl inhibitor Phase II
Sorafenib Kinase inhibitor Flt3, C-KIT, PDGFRbeta, RET, Raf kinase B, Raf kinase C, VEGFR-1, KDR, FLT4 Multi-kinase inhibitor Launched-2005
TKI258 Kinase inhibitor EGFR, FGFR1, PDGFRbeta, VEGFR-1, KDR Multi-kinase inhibitor Phase III
PD-0332991 Kinase inhibitor CDK4/6 CDK4/6 Inhibitor Phase II
AEW541 Kinase inhibitor IGF-1R IGF-1R Inhibitor Preclinical
RAF265 Kinase inhibitor Raf kinase B, KDR Raf kinase B and KDR Inhibitor Phase I
PLX4720 Kinase inhibitor RAF Raf kinase B Inhibitor Preclinical
PD-0325901 Kinase inhibitor MEK MEK1 and MEK2 Inhibitor Discontinued
AZD6244 Kinase inhibitor MEK MEK1 and MEK2 Inhibitor Phase II
Nutlin-3 Other targeted therapies MDM2 MDM2 Inhibitor Preclinical
LBW242 Other targeted therapies IAP Inhibitor of Apoptosis Proteins (IAP) Inhibitor Preclinical
17-AAG Other targeted therapies HSP90 Heat Shock Protein 90 (hsp90) Inhibitor Phase III
L-685458 Other targeted therapies Gamma Secretase gamma-Secretase Inhibitor Preclinical
Panobinostat   Other targeted therapies HDAC Histone Deacetylase (HDAC) Inhibitor Pre-Registered
Paclitaxel Cytotoxic beta-tubulin Microtubule-Stabilizing Agents Launched-1993
Irinotecan Cytotoxic Topoisomerase I DNA Topoisomerase I Inhibitor Launched-1994
Topotecan Cytotoxic Topoisomerase I DNA Topoisomerase I Inhibitor Launched-1996